We rank companies based on fund manager, research analyst and news sentiment
ATNM stock icon

Actinium Pharmaceuticals
ATNM

$6.85
2.7%
 

About: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Employees: 49

0
Funds holding %
of 6,474 funds
Analysts bullish %
0
News positive %
of 4 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

42% more call options, than puts

Call options by funds: $500K | Put options by funds: $354K

0% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 18

0.53% less ownership

Funds ownership: 21.34% [Q3] → 20.81% (-0.53%) [Q4]

3% less funds holding

Funds holding: 58 [Q3] → 56 (-2) [Q4]

15% less capital invested

Capital invested by funds: $34.1M [Q3] → $29M (-$5.14M) [Q4]

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

Research analyst outlook

We haven’t received any recent analyst ratings for ATNM.

Financial journalist opinion

Based on 4 articles about ATNM published over the past 30 days

Neutral
PRNewsWire
1 month ago
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
Actinium's cyclotron produced Actinium-225 material has demonstrated radiochemical and radionuclidic purity identical to current gold-standard methods and has the potential to be significantly lower cost at commercial scale than currently available production methods  Proprietary manufacturing technology supported by 5 issued U.S. patents, 49 issued international patents and significant technical know-how Actinium to commit to multi-million-dollar investment and pursue collaborations on a global basis to scale its technology for commercial purposes to support internal programs and address growing demand for Actinium-225 NEW YORK , March 11, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody-Radio Conjugates (ARCs) and other targeted radiotherapies, today announced that it has launched a strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 (Ac-225) leveraging its propriety cyclotron-based method. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA for which there is no known resistance or repair mechanism, making it a highly sought after isotope for targeted radiotherapies.
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
Neutral
PRNewsWire
1 month ago
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
- Active relapsed or refractory AML patients 65+ years receiving an Iomab-B led Bone Marrow Transplant (BMT) achieved significant improvement in survival at one and two years compared to control arm patients none of whom survived even one year - Unprecedented 100% BMT access and engraftment in evaluable patients receiving a therapeutic dose of Iomab-B despite high leukemia burden and multiple lines of prior treatment - Iomab-B has also demonstrated improved outcomes in patients with high-risk features including a TP53 mutation NEW YORK , Feb. 26, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported new analyses from the positive Phase 3 SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT® (American Society for Transplantation and Cellular Therapy and CIBMTR®  (Center for International Blood and Marrow Transplant Research). The presentations reported unprecedented 100% access to potentially curative bone marrow transplant (BMT) and engraftment in evaluable patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and improved long-term survival outcomes greater than 2 years in patients age 65 or older.
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®